Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment

European Journal of Pharmacology

Volumn 522, Issue 1-3, 2005, Pages 122-129

  Djazayeri, Katayoun ^a   Szilvássy, Zoltán ^a   Peitl, Barna ^a   Németh, József ^b   Nagy, László ^a   Kiss, Attila ^a   Szabó, Boglárka ^a   Benko, Ilona ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

Author keywords

CFU GM (Granulocyte macrophage progenitor cell); Insulin; Myeloprotection; Neutropenia; Rosiglitazone; Stem cell

Indexed keywords

FLUOROURACIL; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW; BONE MARROW CELL; BONE MARROW TOXICITY; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GRANULOCYTE PRECURSOR; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANILIDES; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BLOOD GLUCOSE; BONE MARROW; BONE MARROW CELLS; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; GRANULOCYTE PRECURSOR CELLS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAPERITONEAL; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 26844505771     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.08.053     Document Type: Article

References (30)

1. I. Benko, F. Hernádi, A. Megyeri, A. Kiss, G. Somogyi, Z. Tegyey, F. Kraicsovits, and P. Kovács Comparison of toxicity of fluconazole and other azole antifungal drugs to murine and human granulocyte-macrophage progenitor cells (CFU-GM) in vitro J. Antimicrob. Chemother. 43 1999 675 681
2. I. Benko, P. Kovács, I. Szegedi, A. Megyeri, A. Kiss, E. Balogh, É. Oláh, J. Kappelmayer, and C. Kiss Effect of myelopoietic and pleiotropic cytokines on colony formation by blast cells of children with acute lymphoblastic leukemia Naunyn-Schmiedeberg's Arch. 2000 499 508
3. I. Benko, K. Djazayeri, C. Ábrahám, J. Zsuga, and Z. Szilvássy Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil Eur. J. Pharmacol. 477 2003 179 182
4. B.D. Bennett, G.P Solar, J.Q Yuan, J. Mathias, G.R Thomas, and W.A. Matthews Role for leptin and its cognate receptor in hematopoiesis Curr. Biol. 6 1996 1170 1180
5. G.P. Bodey, E.J. Anaissie, L.S. Elting, E. Estey, S. O'Brien, and H. Kantarjian Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B Cancer 73 1994 2009 2106
6. P.A. Denning-Kendall, A. Nicol, H. Horsley, C. Donaldson, B. Bradley, and J.M. Hows Is in vitro expansion of human cord blood cells clinically relevant? Bone Marrow Transplant. 21 1998 225 232
7. M.R. Difalco, L. Dufresne, and L.F. Congote Efficacy of an insulin-like growth factor-interleukin-3 fusion protein in reversing the hematopoietic toxicity associated with azidothymidine in mice J. Pharmacol. Exp. Ther. 284 1998 449 454
8. J. Dunst, S. Semlin, S. Pigorsch, A.C. Muller, and T. Reese Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients Strahlenther. Onkol. 176 2000 416 421
9. M. Esser, and H. Brunner Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia Pharmacoeconomics 21 2003 1295 1313
10. S. Fujimura, J. Suzumiya, K. Nakamura, and J. Ono Effects of troglitazone on the growth and differentiation of hematopoietic cell lines Int. J. Oncol. 13 1998 1263 1267
11. S. Fulda, I. Fichtner, B. Hero, and F. Berthold Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients Med. Pediatr. Oncol. 36 2001 199 202
12. M.E. Green, J. Pitts, M.A. McCarville, X.S. Wang, J.A. Newport, C. Edelstein, F. Lee, S. Ghosh, and S. Chu PPARg: observations in the hematopoietic system Prostaglandins Lipid Med. 62 2000 45 73
13. J.T. Hartmann, A. von Vangerow, L.M. Fels, S. Knop, H. Stolte, L. Kanz, and C. Bokemeyer A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation Br. J. Cancer 84 2001 313 320
14. H.G. Heuft, L. Goudeva, and R. Blasczyk A comparative study of adverse reactions occurring after administration of glycosylated granulocyte colony stimulating factor and/or dexamethasone for mobilization of neutrophils in healthy donors Ann. Hematol. 83 2004 279 285
15. K.T. Iida, H. Suzuki, H. Sone, H. Shimano, H. Toyoshima, S. Yatoh, T. Asano, Y. Okuda, and N. Yamada Insulin inhibits apoptosis of macrophage cell line, THP-1 cells, via phosphatidylinositol-3-kinase-dependent pathway Arterioscler. Thromb. Vasc. Biol. 22 2002 380 386
16. S. Kersten Peroxisome proliferator activated receptors and obesity Eur. J. Pharmacol. 440 2002 223 234
17. J.G. Kuhn Chemotherapy-associated hematopoietic toxicity Am. J. Health-Syst. Pharm. 59 2002 S4 S7
18. A.F. List, R. Heaton, B. Glinsmann-Gibson, and R.L. Capizzi Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors Leukemia 12 1998 1596 1602
19. R. Mossner, U. Schulz, U. Kruger, P. Middel, S. Schinner, L. Fuzesi, C. Neumann, and K. Reich Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma J. Invest. Dermatol. 119 2002 576 582
20. K. Ohta, T. Endo, K. Haraguchi, J.M. Hershman, and T. Onaya Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells J. Clin. Endocrinol. Metab. 86 2001 2170 2177
21. J. Ratajczak, Q. Zhang, E. Pertusini, B.S. Wojczyk, M.A. Wasik, and M.Z. Ratajczak The role of insulin and insulin-like groth factor-1 in regulating human erythropoiesis Leukemia 12 1998 371 381
22. S. Rutella, L. Pierelli, C. Rumi, G. Bonanno, M. Marone, S. Sica, E. Capoluongo, F. Ameglio, G. Scambia, and G. Leone T-cell apoptosis induced by granulocyte colony-stimulating factor is associated with retinoblastoma protein phosphorylation and reduced expression of cyclin-dependent kinase inhibitors Exp. Hematol. 29 2001 401 415
23. O. Seda, L. Kazdova, D. Krenova, and V. Kren Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndromeX Folia Biol. (Praha) 48 2002 237 241
24. M. Toyoda, H. Takagi, N. Horiguchi, S. Kakizaki, K. Sato, H. Takayama, and M. Mori A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells Gut 50 2002 563 567
25. G. Tsarfaty, D.L. Longo, and W.J. Murphy Human insulin-like growth factor I exerts hematopoietic growth-promoting effects after in vivo administration Exp. Hematol. 22 1994 1273 1277
26. J. Vamecq, and N. Latruffe Medical significance of peroxisome proliferator-activated receptors Lancet 354 1999 141 148
27. H. Walter, and G. Lubben Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus Drugs 65 2005 1 13
28. Y.L. Wang, K.A. Frauwirth, S.M. Rangwala, M.A. Lazart, and C.B. Thompson Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival J. Biol. Chem. 277 2002 31781 31788
29. C.H. Wang, N. Ciliberti, S.H. Li, P.E. Szmitko, R.D. Weisel, P.W. Fedak, M. Al-Omran, W.J. Cherng, R.K. Li, W.L. Stanford, and S. Verma Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy Circulation 109 2004 1392 1400
30. W.S. Zawalich, G. Tesz, and K.C. Zawalich Contrasting effects of nateglinide and rosiglitazone on insulin secretion and phospholipase C activation Metabolism 52 2003 1393 1399